anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a cyclopropachromenecarboxylic acid derivative, having antagonistic actions on metabolism regulation type glutamic acid receptors and useful for improving and treating various symptoms derived from functional and organic disorders. CONSTITUTION: A derivative of the formula (A is O, hydroxyimino, etc.; B is COOR<3> , etc.; R<3> is H or a 1-5C alkyl; X is a halogen, etc.), e.g. 1a- ethoxycarbonyl-1a, 7a-dihydro-7 (1H)-cyc lopropa [b] chromen-7-one. The compound of the formula is obtained by esterifying or amidating a 4-oxo-4H-1- benzopyran-2-carboxylic acid derivative, further treating the resultant compound with 1-10 equiv. trimethylsulfoxonium iodide in the presence of l-10 equiv. alkali metallic base such as Na or K in a solvent such as dimethyl sulfoxide or dimethylformamide, preferably at ambient temperature to 60 deg.C. The derivative is useful as a therapeutic agent for disorders such as sequelae of cerebral infarction or senile dementia.
INTRODUCTION: Parastomal hernia repair is a real surgical challenge because of the high rate of recurrence. The Stapled Mesh Stoma Reinforcement Technique (SMART) is a keyhole-like technique in which the mesh is stapled to the fascia using a circular mechanical stapler.
METHODS: A prospective study from January 2021 to February 2023 was conducted including all patients operated with the SMART technique. Primary endpoint was the recurrence rate during the follow-up. Secondary endpoints were reoperation, Surgical site Occurrence (SSO) and deep (mesh) surgical site infection (SSI) within 30 days postoperatively.
RESULTS: Sixteen patients operated on SMART procedures were included. The mean follow-up was 11.3 ± 9.2 months. The SSO rate was 18.7% (n = 3). A seroma was drained radiologically (IIIa), one haematoma was evacuated surgically (IIIb) and one patient presented a postoperative lesion of a ureter after a parastomal Bricker's hernia repair. In addition, there was one death due to multiple organ failure (V). There was no SSI. The recurrence rate was 57.1% during the follow-up.
CONCLUSION: This study shows disappointing results for this SMART technique, with a high recurrence rate.
PURPOSE:To obtain a solid powdery cosmetic having excellent mold-releasability and beautifully finished surface appearance, by inserting a releasant-containing press sheet between a press head and a solid powdery cosmetic in the press forming of the cosmetic. CONSTITUTION:A definite amount of a solid powdery cosmetic is put into an intermediate dish fixed to a mounting table and the surface of the cosmetic is covered with a press sheet impregnated or coated with a releasant. A formed solid powdery cosmetic can be produced by pressing the cosmetic with a press head in a state providing the press sheet between the press head and the solid powdery cosmetic. The releasant is selected from an oleophilic surfactant of <=5 HLB (e.g. sorbitan monooleate), a hydrocarbon which is liquid at normal temperature (e.g. liquid paraffin), a volatile silicone (e.g. methylpolysiloxane), an oleophilic surfactant having an HLB of >=10 [e.g. POE(7.5)-nonyl phenyl ether] and a polyhydric alcohol (e.g. glycerol).
Provided is a cosmetic gel sheet suited for the beauty field and the medical field.　This cosmetic gel sheet comprises a gel sheet comprising a water-soluble carboxylated polymer, a polyhydric alcohol, and an acid as essential constituent ingredients and wafer paper superposed as a support on one or both surfaces of the gel sheet. Carboxylated polysaccharides are suitable for use as the water-soluble carboxylated polymer. The gel sheet has a water content of 30 wt% or less, and the water content thereof is more preferably 20 wt% or less. In this cosmetic gel sheet, the gel sheet can be produced by drying an aqueous solution containing a water-soluble carboxylated polymer, a polyhydric alcohol, and an acid as essential ingredients. When doing so, it is desirable that the acid content in the aqueous solution is suitable for making the aqueous solution have a pH of 2.0-4.5.
PURPOSE: A composition of a radiation sensitizing agent which contains an extract of Fomitella fraxinea(Bull.: Fr.) Ryv. as an active ingredient is provided to minimize adverse effect of radiation and to allow the composition to exhibit excellent sensitizing effect on radiation. CONSTITUTION: The composition of a radiation sensitizing agent contains 0.01 to 50% by weight of an extract of Fomitella fraxinea obtained by extraction with a solvent selected from ethanol, methanol, butanol and propanol. For an example, Fomitella fraxinea is dried and ground. 50g of Fomitella fraxinea powder is extracted in 10L aqueous methanol solution, followed by reaction at 40deg.C for 3 days, filtration and freeze- drying to produce 150g of Fomitella fraxinea extract. The composition has an LD50 value of 400mg/1kg(body weight).
PURPOSE:A powder cosmetic, having improved water and oil absorption effects and durability, and comprising porous powder and/or hollow porous powder, and a saccharide in a specific proportion in a cosmetic consisting of a powder base mainly. CONSTITUTION:A powder cosmetic composition comprising (A) 0.5-20wt%, preferably 2-10wt%, porous powder and/or hollow porous powder, (B) 0.5-20wt%, preferably 1.5-8wt%, a saccharide and/or its glycoside or derivative and (C) a powder base, e.g. talc, and if necessary an oil. Magnesium silicate, calcium silicate and calcium carbonate may be cited as the porous powder. Monosaccharide, oligosaccharide, polysaccharide and musosaccharide may be cited as the saccharide. The composition in a loose or pressed form provides a wide range of feeling of use by selecting the components and compounding ratio.
A method, system, medium, and implementations for computer-aided preoperative surgical planning are described. Input data acquired with respect to a part of a patient is received by the system. The part corresponds to an organ, e.g., lung, of the patient to be operated on and includes one or more lesions to be removed during an operation. Then, an anatomic 3D model of the part of the patient is generated. Based on the generated anatomic 3D model, a preoperative plan for linear-cutting stapler resection of the one or more lesions from the organ to be carried out during the operation is obtained. The stapler cartridge size and the staple length are estimated based on the preoperative plan. Further, the resection based on the preoperative plan is visualized.
Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb\>9g/dL, and this will be maintained throughout their hospitalization.
Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
Epidemiological evidence from several countries supports a protective effect of fish consumption on cancer risk and gastrointestinal cancers in particular. Further evidence to support the idea that fish consumption is protective in relation to cancers of the GI tract is now emerging from the European Investigation into Cancer and Nutrition (EPIC).

The FISHGASTRO project is headed by the Institute of Food Research and includes groups from the University of East Anglia, the University of Wageningen, Netherlands and the University of Jena, Germany. The project focuses on assessing the impact of fish consumption on a range of markers of gastrointestinal health associated with ulcerative colitis or colon cancer and on looking at bio-accessibility of a range of nutrients from fish. We aim to recruit a total of 270 patients with gastrointestinal problems in the UK and Netherlands and take biopsy and blood samples before and after asking them to eat two extra portions of fish per week. One group will receive oil rich fish such as salmon while another will be asked to eat white fish. Changes in cell proliferation, apoptosis, inflammatory markers, gene expression and plasma levels of n-3 fatty acids will be compared to a control group only given standard nutritional advice.
The placebo arm will be matched to study drug to maintain the study blind. Regular Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab twice a day for 4 consecutive days (5 days in total) Modified Dose Placebo 2 tabs once, followed in 8 hours by 2 tabs, then 1 tab once a day for 4 consecutive days (5 days in total) Modified doses are for individuals with body weight below 40 kg, renal impairment with a creatinine clearance less than 10mls/min or QTc interval greater than 480 but less than 500.
The primary outcome was the incidence of POD within 3 days postoperatively. The patients will be randomly split into two datasets with split ratios of 80% and 20%.

Subsequently, 80% of the patients will be used for training, and 20% of the patients will be used for testing. Multiple machine learning algorithms will be used to develop POD risk prediction models. The discrimination ability of the prediction models will be assessed by calculating the area under the receiver operating characteristic curve (AUC). The calibration of the model will be evaluated using the Hosmer-Lemeshow goodness of fit test. Decision curve analysis (DCA) will be used to evaluate the net benefits for each threshold probability. The best model will be selected by comparing the performance between the models. Then the SHapley Additive exPlanations (SHAP) will be used to explain the best one.
Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
The invention relates to methods for predicting the survival time of patients suffering from pancreatic ductal adenocarcinoma (PDA) and methods for the treatment of PDA. The inventors investigated the role of Pancreatitis Associated Protein (PAP/REG3A) as prognostic marker associated with PDA, evaluated its implication in PDA associated nervous system alterations (peri-neural invasion (PNI)) and its impact on PDAs' patients survival. Using an  exvivo  assay, they determined its influence on PNI and correlated it with the prognostic value of PAP/REG3A as a circulating biomarker. They demonstrated that PAP/REG3A enhance cancer cells migration and invasion abilities. By activating JAK/STAT signaling pathways, PAP/REG3A favors PNI, known to be associated with relapse after surgery. They also analyzed the level of PAP/REG3A in serum from healthy donors or patients with PDA from three different cohorts and demonstrate that PAP/REG3A is a biomarker of shorter survival as well as poor surgical outcomes with reduced disease-free survival. Thus, the invention relates to a method for predicting the survival time of a patient suffering from PDA and REG3A inhibitors for use in the treatment of PDA.
The present invention relates to cultured cells of Quillaja sp. For the preparation of active substances from Quillaja sp., such as saponins. The cells may either originate from a callus tissue culture or from a suspension cell culture. Preferred Quillaja sp. are species selected from the group consisting of Quillaja saponaria Molina, Quillaja smegmadermos, Quillaja brasiliesis. The invention further relates to active substances extracted from cultured cells of Quillaja sp. and to preparations comprising these active substances, or a non-dialysable or a dialysable fraction thereof, to methods for preparing the active substances and to various agents, comprising the dialyzable and/or the non-dialysable fraction of an extract of cultured cells of Quillaja sp. And having various properties.
There is provided an amino acid sequence comprised within the PV E1 protein region A delineated by amino acids 352 and 439, and any derivative variant or fragment thereof, necessary for the oligomerization of the E1 protein. This amino acid sequence is capable of self-association and of associating with the full length E1 protein and any derivative, variant or fragment thereof comprising the sequence of this invention. A specific aspect of this first embodiment, the amino acid domain of this invention delimited by amino acids 353 to 438 of the PV E1 protein. More particularly, the amino acid domain of this invention is as defined by SEQ ID NO. 2. There is also provided a cross-linking assay to directly measure the level of oligomerization (or inhibition thereof) of the E1 protein. In accordance with a fourth embodiment of this invention, there is provided a N-terminally truncated E1 protein. More particularly, one aspect of this fourth embodiment encompasses the E1 protein delimited by amino acid 72 to 649 (SEQ ID No. 78).
During the study, participants will be asked to take ENMD-2076 once a day, everyday. Every 28 days will be called a cycle. While receiving the study drug, participants will be asked to visit the clinic for tests and procedures. During Cycle 1, participants will be asked to visit the clinic about once a week and during Cycle 2 and future cycles, participants will be asked to visit the clinic on days 1 and 15. As a part of the study, tumor tissue (archival and fresh tumor biopsy) will be taken for biomarker research. When participants stop the study drug, they will be asked to have an end of study drug visit.
(See INDICATIONS AND USAGE.)

Azithromycin for oral suspension (single dose 1 g packet) can be taken with or without food after constitution. Not for pediatric use. For pediatric suspension, please refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.

Azithromycin tablets may be taken without regard to food. However, increased tolerability has been observed when tablets are taken with food.

The recommended dose of azithromycin for the treatment of non-gonococcal urethritis and cervicitis due to C. trachomatis is: a single 1 gram (1000 mg) dose of azithromycin. This dose can be administered as one single dose packet (1 g).
Method of modulating tumour cell growth towards normalisation and loss of malignant cell phenotype comprises exposing the tumour cells to exogenous mismatched double-stranded RNA (dsRNA), thus increasing protein synthesis and loss of malignant cell phenotype. Method of restoring dsRNA to a patient having a tumour whose cells are deficient in dsRNA comprises admin. of a mismatched dsRNA until the intracellular dsRNA deficiency is restored and corrected. - Method of improving the antigrowth activity of an interferon (IFN) is non-responding or sub-responding tumour cells comprises: (i) admin. of a 2',5' A synthetase-activating mismatched dsRNA to the tumour cell mass in amt. sufficient to induce the synthesis of a dsRNA which participates in tumour cell growth regulation in association with IFN; and then (ii) admin. of a tumour-inhibiting amt. of IFN while opt. continuing admin. of the mismatched dsRNA.
This intervention will be delivered using a similar format and schedule as the financial incentive+nutrition education, motivational interviewing and dietary norms intervention group (i.e., 11 community health worker led in-person group based sessions at the Center for Southeast Asians, 3 MI phone calls, and text messages). The content will focus on family-specific family engagement methods to improve children's academic outcomes.
Stroke is a significant public health issue, and research has consistently focused on studying the mechanisms of injury and identifying new targets. As a CDK5 activator, p39 plays a crucial role in various diseases. In this article, we will explore the role and mechanism of p39 in cerebral ischemic injury. We measured the level of p39 using western blot and QPCR at various time points following cerebral ischemia-reperfusion (I/R) injury. The results indicated a significant reduction in the level of p39. TTC staining and behavioral results indicate that the knockout of p39 (p39KO) provides neuroprotection in the short-term. Interestingly, the behavioral dysfunction in p39KO mice was exacerbated after the repair phase of I/R. Further study revealed that this deterioration may be due to demyelination induced by elevated p35 levels. In summary, our study offers profound insights into the significance of p39 in both the acute and repair stages of ischemic injury recovery and a theoretical foundation for future therapeutic drug exploration.
OBJECTIVES: Previously, Interferon-induced Protein with Tetratricopeptide Repeats 1 (IFIT1) has been shown to promote cancer development. Here, we aimed to explore the role of IFIT1 in the development and progression of pancreatic cancer, including the underlying mechanisms.
METHODS: We explored IFIT1 expression in pancreatic cancer samples using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Cell Counting Kit-8 (CCK8), colony formation, scratch wound-healing and Transwell assays were performed to assess the proliferation, migration and invasion abilities of pancreatic cancer cells. Gene Set Enrichment Analysis (GSEA) and Western blotting were performed to assess the regulatory effect of IFIT1 on the Wnt/β-catenin pathway.
RESULTS: We found that upregulation of IFIT1 expression is common in pancreatic cancer and is negatively associated with overall patient survival. Knockdown of IFIT1 expression led to decreased proliferation, migration and invasion of pancreatic cancer cells. We also found that IFIT1 could regulate Wnt/β-catenin signaling, and that a Wnt/β-catenin agonist could reverse this effect. In addition, we found that IFIT1 can promote epithelial-mesenchymal transition (EMT) of pancreatic cancer cells.
CONCLUSIONS: Our data indicate that IFIT1 increases pancreatic cancer cell proliferation, migration and invasion by activating the Wnt/β-catenin pathway. In addition, we found that EMT could be regulated by IFIT1. IFIT1 may serve as a potential therapeutic target for pancreatic cancer.
Lactulose is a synthetic disaccharide in solution form for oral administration. Each 15mL contains: Lactulose 10g (less than 1.6g galactose, less than 1.2g lactose, and 0.1g or less of fructose). It also contains D&C Yellow No. 10, FD & C Yellow No. 6 and Purified Water.   
Lactulose is a colonic acidifier which promotes laxation.   
The chemical name for lactulose is 4-0-ß-D-galactopyranos-D-fructofuranose. It has the following structural formula: 

The molecular weight is 342.30. It is freely soluble in water.
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by swollen joints, discomfort, stiffness, osteoporosis, and reduced functionality. Genetics, smoking, dust inhalation, high BMI, and hormonal and gut microbiota dysbiosis are all likely causes of the onset or development of RA, but the underlying mechanism remains unknown. Compared to healthy controls, patients with RA have a significantly different composition of gut microbiota. It is well known that the human gut microbiota plays a key role in the initiation, maintenance, and operation of the host immune system. Gut microbiota dysbiosis has local or systematic adverse effects on the host immune system, resulting in host susceptibility to various diseases, including RA. Studies on the intestinal microbiota modulation and immunomodulatory properties of probiotics have been reported, in order to identify their potential possibility in prevention and disease activity control of RA. This review summarized current studies on the role and potential mechanisms of gut microbiota in the development and progression of RA, as well as the preventative and therapeutic effects and potential mechanisms of probiotics on RA. Additionally, we proposed the challenges and difficulties in the application of probiotics in RA, providing the direction for the research and application of probiotics in the prevention of RA.
Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
The invention discloses Fructus Forsythiae formula granules, and a preparation method and quality control method thereof. The preparation method comprises the following steps: carrying out aqueous extraction on the raw material Fructus Forsythiae herbal pieces, concentrating under reduced pressure, carrying out spray drying, and the like to obtain the Fructus Forsythiae formula granules. Every gram of Fructus Forsythiae formula granules is equivalent to 11-15 grams of crude drug. The Fructus Forsythiae formula granules are subjected to quality identification by thin-layer chromatography. On the basis of the traditional Chinese medicine decoction, the invention combines the modern high-tech extractor, pharmaceutical technology and thin-layer chromatographic scanning technology, refers to the research of Fructus Forsythiae chemical composition to perform extraction process research and thin-layer chromatography identification method research on the Fructus Forsythiae, thereby obtaining the Fructus Forsythiae formula granules which can be taken by being directly dissolved before use. The medicine can implement complete component extraction, scientific production and controllable quality, and can implement large-scale production. The medicine is convenient and sanitary to take, and convenient for storage.
Prophylactic dissection of paratracheal lymph nodes in clinically lymph node-negative (cN0) papillary thyroid carcinoma (PTC) remains controversial. This study aims to integrate preoperative and intraoperative variables to compare traditional nomograms and machine learning (ML) models, developing and validating an interpretable predictive model for paratracheal lymph node metastasis (PLNM) in cN0 PTC patients. We retrospectively selected 3213 PTC patients treated at the First Affiliated Hospital of Chongqing Medical University from 2016 to 2020. They were randomly divided into the training and test datasets with a 7:3 ratio. The 533 PTC patients treated at the Guangyuan Central Hospital from 2019 to 2022 were used as an external test sets. We developed and validated nine ML models using 10-fold cross-validation and grid search for hyperparameter tuning. The predictive performance was evaluated using ROC curves, decision curve analysis (DCA), calibration curves, and precision-recall curves. The best model was compared to a traditional logistic regression-based nomogram. The XGBoost model achieved AUC values of 0.935, 0.857, and 0.775 in the training, validation, and test sets, respectively, significantly outperforming the traditional nomogram model with AUCs of 0.85, 0.844, and 0.769, respectively. SHapley Additive exPlanations (SHAP)-based visualization identified the top 10 predictive features of the XGBoost model, and a web-based calculator was created based on these features. ML is a reliable tool for predicting PLNM in cN0 PTC patients. The SHAP method provides valuable insights into the XGBoost model, and the resultant web-based calculator is a clinically useful tool to assist in the surgical planning for paratracheal lymph node dissection.
Patient is in prone lying position with foot supported. Pressure is applied with the heel of the opposite hand, while a stroke in the shape of the letter J is applied in the direction of the restriction, with two or three fingers, which creates some torque at the end. Myofascial Release techniques will be performed for 20 repetitions.